A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864 · eVOLVE-HNSCC Phase 3Recruiting
- Lead sponsor
- AstraZeneca (Industry)
- Enrollment
- 1,145 (estimated)
- Start date
- 14 Dec 2023
- Primary completion
- 17 Apr 2030 (estimated)
- Study completion
- 28 Feb 2031
- Last update posted
- 30 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Single
- Arms
- 2
Interventions
- volrustomig Drug
Conditions and primary outcome
- Locally Advanced Head and Neck Squamous Cell Carcinoma
Primary outcome
Progression-Free Survival (PFS) in participants with unresected LA-HNSCC with PD-L1 expressing tumors (Up to approximately 8 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06129864.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06129864 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.